genOway signs a three-year contract with a global philanthropic organization supporting the development of infectious diseases therapies

Lyon, France – February 21, 2025 – genOway is a biotechnology company specializing in the development of predictive preclinical solutions (better mimicking human physiology and disease), enabling pharmaceutical research players to select the safest and most effective drug candidates.

In December 2024, genOway and the Gates Foundation signed a three-year contract to incorporate the genO-hFcγR mouse model into the foundation’s global health research initiatives.

The genO-hFcγR mouse model – an innovative preclinical model to assess the efficacy and safety of a large range of therapeutic antibodies – aims to accelerate predictive preclinical studies of new therapies for infectious diseases funded by the foundation worldwide.

Through this agreement, genOway will partner on projects involving the genO-hFcγR model with grantees of the foundation who are doing research in infectious diseases, such as HIV/AIDS, COVID-19, malaria, polio and influenza.

“We are thrilled and honored by this new funding from the Gates Foundation. Supporting, through our preclinical platform, the constant effort of the foundation to improve global health, expand access to education and technology, and fight inequities around the world, means a lot to genOway. Through our genO-hFcγR mouse model, we will support the foundation’s efforts to identify and profile novel therapeutic antibodies for infectious diseases.” ​– Kader Thiam, Senior Vice President – Discovery, Preclinical Models & Services at genOway